Policy | June 26, 2024
CCRAS hosts national consultative meet on traditional medicine
Signs MoUs with Shri Krishna Ayush University and Dabur India
Signs MoUs with Shri Krishna Ayush University and Dabur India
Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care
The consultative meet, a first of its kind, will bring together representatives from diverse domains of Traditional Medicine (TM) in India
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Subscribe To Our Newsletter & Stay Updated
